Skip to main content
SpringerLink
Log in

Atezolizumab: First Global Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Atezolizumab (Tecentriq™)—a monoclonal antibody targeting programmed death ligand 1 (PD-L1 or CD274 antigen)—is being developed by Genentech as treatment for a variety of haematological malignancies and solid tumours. It been approved in the US as a second-line therapy for urothelial carcinoma and is awaiting approval as a second-line therapy for non-small cell lung cancer. This article summarizes the milestones in the development of atezolizumab leading to this first approval for urothelial carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. FDA. FDA approves new, targeted treatment for bladder cancer [media release]. 6 Jun 2016. http://www.fda.gov.

  2. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Genentech Inc. Prescribing information for Tecentriq™ (atezolizumab) injection, for intravenous use. 2016. http://www.gene.com/download/pdf/tecentriq_prescribing.pdf. Accessed 20 May 2016.

  4. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.

    Article  CAS  PubMed  Google Scholar 

  5. Petrylak DP, Powles T, Bellmunt J, et al. A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC) [abstract no. 4501]. J Clin Oncol. 2015;33(Suppl).

  6. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46.

    Article  CAS  PubMed  Google Scholar 

  7. Besse B, Johnson M, Janne PA, et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) [abstract no. 16LBA]. Eur J Cancer. 2015;51(Suppl 3):S717–8.

    Article  Google Scholar 

  8. Spigel DR, Chaft JE, Gettinger SN, et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC) [abstract no. 8028]. J Clin Oncol. 2015;33(Suppl).

  9. Camidge R, Liu SV, Powderly J, et al. Atezolizumab (MPDL3280A) combined with platinum-based chemotherapy in non-small cell Lung cancer (NSCLC): a phase Ib safety and efficacy update [abstract no. ORAL02.07]. J Thorac Oncol. 2015;10(9 Suppl 2):S176–7.

    Google Scholar 

  10. Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) [abstract no. 2859]. Cancer Res. 2015;75(15 Suppl).

  11. Adams S, Diamond J, Hamilton E, et al. Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer [abstract no. P2-11-06]. Cancer Res. 2016;76(4 Suppl).

  12. McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016;10(34):833–42.

    Article  Google Scholar 

  13. Sznol M, McDermott DF, Jones SF, et al. Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract no. 410]. J Clin Oncol. 2015;33(Suppl 7).

  14. Bendell J, Kim TW, Goh BC, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC) [abstract no. 3502]. J Clin Oncol. 2016;34(Suppl).

  15. Boyd Z, Smith D, Baker B, et al. Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab [abstract no. B001]. Cancer Immunol Res. 2016;4(Suppl).

  16. Castellano D, Albers P, Gschwend JE, et al. A phase III study of the efficacy and safety of adjuvant atezolizumab (anti-PDL1) vs observation in patients with muscle-invasive urothelial carcinoma of the bladder (IMvigor 010) [abstract]. Eur Urol. 2016;15(3 Suppl).

  17. Herbst RS, De Marinis F, Jassem J, et al. Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1-selected chemotherapy-naive patients with advanced NSCLC [abstract no. 355TiP]. Ann Oncol. 2015;26(Suppl 9):i105–6.

    Google Scholar 

  18. Mok TSK, Cappuzzo F, Jotte RM, et al. Phase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC [abstract no. 356TiP]. Ann Oncol. 2015;26(Suppl 9):ix106.

    Article  Google Scholar 

  19. Rizvi NA, Chow LQM, Dirix LY, et al. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC) [abstract no. TPS8123]. J Clin Oncol. 2014;32(5 Suppl).

  20. Emens L, Adams S, Loi S, et al. A phase III randomized trial of atezolizumab in combination with nab- paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC) [abstract no. OT1-01-06]. Cancer Res. 2015;76(4 Suppl).

Download references

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Anthony Markham

Authors
  1. Anthony Markham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony Markham.

Ethics declarations

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis, Springer SBM.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

This article in the topical Collection on Immuno-Oncology.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Markham, A. Atezolizumab: First Global Approval. Drugs 76, 1227–1232 (2016). https://doi.org/10.1007/s40265-016-0618-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-016-0618-8

Keywords

Search

Navigation